AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14660479 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 8
Study 11466160 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 6
Study 9684717 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 52
Study 9684717 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright position
Number of subjects: 52
Study 9684717 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position (1 week after implantation)
Number of subjects: 52
Study 9684717 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright position (1 week after implantation)
Number of subjects: 52
Study 9684717 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position (3 months after implantation)
Number of subjects: 52
Study 9684717 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright position (3 months after implantation)
Number of subjects: 52
Study 9684717 — intervention group
Group type: EXPERIMENTAL
Intervention: Both body positions
Number of subjects: 52
Study 7889225 — intervention group
Group type: EXPERIMENTAL
Intervention: AB/BA design
Number of subjects: 0
Study 7889225 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage procedure
Number of subjects: 0
Study 7889225 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of covariance
Number of subjects: 0
Study 3126306 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 20-40 mg kg‐1
Number of subjects: 0
Study 3126306 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 30-40 mg kg‐1
Number of subjects: 0
Study 3126306 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of praziquantel
Number of subjects: 0
Study 30412630 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (enoxaparin)
Number of subjects: 242
Study 30412630 — intervention group
Group type: COMPARATOR
Intervention: Control (not receiving low molecular weight heparin)
Number of subjects: 242
Study 27291074 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of occupational physical activity (OPA)
Number of subjects: 385
Study 24895813 — intervention group
Group type: EXPERIMENTAL
Intervention: Mononuclear cells (MNCs)
Number of subjects: 4
Study 24895813 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+ cells
Number of subjects: 4
Study 24895813 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 4
Study 22440072 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Cognitive Therapy (MBCT)
Number of subjects: 52
Study 22440072 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 52
Study 20536800 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat therapy (n = 31)
Number of subjects: 60
Study 20536800 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold therapy (n = 29)
Number of subjects: 60
Study 18414370 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 96
Study 18414370 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 96
Study 15536472 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg soybean‐derived pinitol, twice daily for 13 weeks
Number of subjects: 30
Study 15536472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12488371 — intervention group
Group type: COMPARATOR
Intervention: Standard Macintosh laryngoscope
Number of subjects: 20
Study 12488371 — intervention group
Group type: EXPERIMENTAL
Intervention: Five single-use laryngoscopes
Number of subjects: 20
Study 12488371 — intervention group
Group type: EXPERIMENTAL
Intervention: Four single-use laryngoscopes
Number of subjects: 20
Study 12488371 — intervention group
Group type: EXPERIMENTAL
Intervention: All laryngoscopes tested
Number of subjects: 20
Study 12488371 — intervention group
Group type: EXPERIMENTAL
Intervention: Reusable Macintosh laryngoscope
Number of subjects: 20
Study 11531789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ointment (O)
Number of subjects: 29
Study 11531789 — intervention group
Group type: COMPARATOR
Intervention: Cream (C)
Number of subjects: 29
Study 11531789 — intervention group
Group type: COMPARATOR
Intervention: Solution (S)
Number of subjects: 29
Study 11531789 — intervention group
Group type: COMPARATOR
Intervention: Low-viscosity cream (LVC)
Number of subjects: 29
Study 9257795 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuMAb‐E25 (0.15 mg/kg subcutaneously, 0.15 mg/kg intravenously, or 0.5 mg/kg intravenously)
Number of subjects: 240
Study 9257795 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneous and intravenous)
Number of subjects: 240
Study 9257795 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuMAb‐E25
Number of subjects: 240
Study 8501148 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist plus estrogen-progestin add-back regimen
Number of subjects: 51
Study 8501148 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist plus progestin add-back regimen
Number of subjects: 51
Study 3327939 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with protein-free artificial surfactant (ALEC)
Number of subjects: 0
Study 31994022 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT‐709478 30 mg once daily for 12 days
Number of subjects: 46
Study 31994022 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT‐709478 10 mg once daily for 12 days
Number of subjects: 46
Study 31994022 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT‐709478 10, 30, and 60 mg for 7 days each, then 100 mg once daily for 8 days
Number of subjects: 46
Study 31994022 — intervention group
Group type: COMPARATOR
Intervention: ACT‐709478 60 mg and 100 mg with midazolam
Number of subjects: 46
Study 31994022 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT‐709478
Number of subjects: 46
Study 30574771 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sea salt-based oral rinse with xylitol
Number of subjects: 0
Study 30574771 — intervention group
Group type: EXPERIMENTAL
Intervention: Sea salt
Number of subjects: 0
Study 30574771 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol
Number of subjects: 0
Study 30574771 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysozyme
Number of subjects: 0
Study 27501724 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegethon mobile app intervention
Number of subjects: 17
Study 26385664 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia (50-60 vol%)
Number of subjects: 42
Study 26385664 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia (1.1-1.4 vol%)
Number of subjects: 42
Study 26385664 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia
Number of subjects: 42
Study 23881846 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 2305
Study 23881846 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 2305
Study 23881846 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin with major hemorrhage included
Number of subjects: 2305
Study 23881846 — intervention group
Group type: COMPARATOR
Intervention: Aspirin with major hemorrhage included
Number of subjects: 2305
Study 20797382 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (100 or 200 mg/d)
Number of subjects: 387
Study 20797382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 387
Study 20797382 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Number of subjects: 387
Study 18592146 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (methylprednisolone 40 mg/day)
Number of subjects: 58
Study 18592146 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600 mg/day)
Number of subjects: 58
Study 18592146 — intervention group
Group type: COMPARATOR
Intervention: Basal treatment (regular ipratropium bromide and beta‐2 agonist as needed) + placebo CS + placebo NAC
Number of subjects: 58
Study 18592146 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal treatment + placebo CS + N-acetylcysteine (600 mg/day)
Number of subjects: 58
Study 16365178 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide plus dexamethasone
Number of subjects: 207
Study 16365178 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone alone
Number of subjects: 207
Study 14584228 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication review and discharge counselling (Intervention group)
Number of subjects: 216
Study 14584228 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 216
Study 10922430 — intervention group
Group type: EXPERIMENTAL
Intervention: Double bolus reteplase (10 + 10 U)
Number of subjects: 50
Study 10922430 — intervention group
Group type: EXPERIMENTAL
Intervention: Front-loaded alteplase (up to 100 mg)
Number of subjects: 50
Study 10922430 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 healthy persons)
Number of subjects: 50
Study 8757514 — intervention group
Group type: EXPERIMENTAL
Intervention: DAT 3 + 10 (daunorubicin for 3 days, cytarabine and 6‐thioguanine for 10 days)
Number of subjects: 972
Study 8757514 — intervention group
Group type: EXPERIMENTAL
Intervention: MAZE (m‐AMSA, 5‐azacytidine, etoposide)
Number of subjects: 972
Study 8757514 — intervention group
Group type: COMPARATOR
Intervention: COAP (cyclophosphamide, vincristine, cytarabine, prednisone)
Number of subjects: 972
Study 8757514 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 year of outpatient maintenance treatment
Number of subjects: 972
Study 8757514 — intervention group
Group type: COMPARATOR
Intervention: DAT 1 + 5 (daunorubicin for 1 day, cytarabine and 6‐thioguanine for 5 days)
Number of subjects: 972
Study 31757197 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 28
Study 31757197 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 28
Study 30902918 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib (12 mg once daily, 2 weeks on/1 week off)
Number of subjects: 133
Study 30902918 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib (50 mg once daily, 4 weeks on/2 weeks off)
Number of subjects: 133
Study 30902918 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 133
Study 30902918 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 133
Study 30471800 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth Care Without a Battle (MCWB) protocol training for NH staff for 2 years
Number of subjects: 219
Study 26169349 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention (3 times a week for 12 weeks)
Number of subjects: 80
Study 26169349 — intervention group
Group type: COMPARATOR
Intervention: Control group (no text messages)
Number of subjects: 80
Study 24583275 — intervention group
Group type: EXPERIMENTAL
Intervention: Gambling involvement (gamblers)
Number of subjects: 427
Study 24583275 — intervention group
Group type: EXPERIMENTAL
Intervention: High impulsivity gamblers
Number of subjects: 427
Study 24583275 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gamblers
Number of subjects: 427
Study 24583275 — intervention group
Group type: COMPARATOR
Intervention: Non-gamblers
Number of subjects: 427
Study 21945145 — intervention group
Group type: EXPERIMENTAL
Intervention: Groshong Catheter
Number of subjects: 26
Study 21945145 — intervention group
Group type: EXPERIMENTAL
Intervention: PI Catheter
Number of subjects: 26
Study 18448745 — intervention group
Group type: EXPERIMENTAL
Intervention: CDB-2914 10 mg daily (T1)
Number of subjects: 22
Study 18448745 — intervention group
Group type: EXPERIMENTAL
Intervention: CDB-2914 20 mg daily (T2)
Number of subjects: 22
Study 18448745 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 22
Study 18448745 — intervention group
Group type: EXPERIMENTAL
Intervention: CDB-2914
Number of subjects: 22
Study 17217710 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20 mg
Number of subjects: 287
Study 17217710 — intervention group
Group type: COMPARATOR
Intervention: Losartan potassium 50 mg
Number of subjects: 287
Study 12559539 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (0.03 U/kg per day)
Number of subjects: 19
Study 12559539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 12559539 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone
Number of subjects: 19
Study 10968443 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased body mass index (BMI) during the first year of life
Number of subjects: 0
Study 10968443 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased growth in length in the next 2 years
Number of subjects: 0
Study 9349571 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT4) 200 microg daily for 12 months
Number of subjects: 101
Study 9349571 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 101
Study 8349327 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg)
Number of subjects: 23
Study 8349327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 2878812 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (DPH) 50 mg b.d.
Number of subjects: 13
Study 2878812 — intervention group
Group type: EXPERIMENTAL
Intervention: Temelastine (SKF) 100 mg b.d.
Number of subjects: 13
Study 2878812 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (DZ) 0.3 mg/kg
Number of subjects: 13
Study 2878812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 29186976 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated sterile water
Number of subjects: 50
Study 29186976 — intervention group
Group type: COMPARATOR
Intervention: ResoClear® impregnation wipes
Number of subjects: 50
Study 26964731 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg sc daily
Number of subjects: 94
Study 26964731 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg sc every 6 months
Number of subjects: 94
Study 26964731 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Teriparatide and Denosumab
Number of subjects: 94
Study 24491076 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-only intervention
Number of subjects: 480
Study 24491076 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined alcohol and alcohol-related RSB intervention
Number of subjects: 480
Study 24491076 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-related RSB-only intervention
Number of subjects: 480
Study 24491076 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 480
Study 22437412 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARBs)
Number of subjects: 1177
Study 22437412 — intervention group
Group type: COMPARATOR
Intervention: Non-renin-angiotensin-aldosterone system (non-RAASi)-based therapy
Number of subjects: 1177
Study 20735818 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based hand disinfectants
Number of subjects: 1230
Study 18495838 — intervention group
Group type: EXPERIMENTAL
Intervention: IG water and ID saline
Number of subjects: 8
Study 18495838 — intervention group
Group type: EXPERIMENTAL
Intervention: ID glucose
Number of subjects: 8
Study 18495838 — intervention group
Group type: COMPARATOR
Intervention: IG water and ID glucose
Number of subjects: 8
Study 17302259 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine therapy for 6-12 months
Number of subjects: 85
Study 14633287 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10750762 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary bypass graft operation
Number of subjects: 0
Study 10750762 — intervention group
Group type: COMPARATOR
Intervention: Cardiopulmonary bypass (CPB)
Number of subjects: 0
Study 8888166 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry mopping with topical and systemic antibiotics and topical steroids
Number of subjects: 524
Study 8888166 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry mopping alone
Number of subjects: 524
Study 8888166 — intervention group
Group type: COMPARATOR
Intervention: No specific treatment (control)
Number of subjects: 524
Study 8888166 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with no otorrhoea
Number of subjects: 524
Study 8888166 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with healed ears
Number of subjects: 524
Study 1410148 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt discontinuation of 6 nights of 0.50 mg triazolam
Number of subjects: 21
Study 1410148 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered discontinuation (3 nights of 0.50 mg, 2 nights of 0.25 mg, and 1 night of 0.125 mg triazolam)
Number of subjects: 21
Study 1410148 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 nights)
Number of subjects: 21
Study 3873784 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT (Tomographic 201‐Tl scintigrams)
Number of subjects: 100
Study 3873784 — intervention group
Group type: COMPARATOR
Intervention: PLAN (Conventional planar images)
Number of subjects: 100
Study 30951920 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic closure of the vaginal cuff after TLH
Number of subjects: 182
Study 30951920 — intervention group
Group type: COMPARATOR
Intervention: Transvaginal closure of the vaginal cuff after TLH
Number of subjects: 182
Study 30951920 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative FSFI score <26.55
Number of subjects: 182
Study 30951920 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral adnexectomy before menopause
Number of subjects: 182
Study 30951920 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative vaginal cuff hematoma
Number of subjects: 182
Study 29078018 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical mucus removal
Number of subjects: 714
Study 29078018 — intervention group
Group type: COMPARATOR
Intervention: Non-mucus removal
Number of subjects: 714
Study 26323809 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-based second-line ART
Number of subjects: 1251
Study 26373226 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate mouthwash (0.2%)
Number of subjects: 105
Study 26373226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon extract
Number of subjects: 105
Study 26373226 — intervention group
Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 105
Study 23390923 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 656
Study 23390923 — intervention group
Group type: COMPARATOR
Intervention: Intravenous t-PA alone
Number of subjects: 656
Study 21916925 — intervention group
Group type: EXPERIMENTAL
Intervention: MI + DVD
Number of subjects: 1021
Study 21916925 — intervention group
Group type: COMPARATOR
Intervention: DVD-only
Number of subjects: 1021
Study 19000581 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant birch pollen allergen vaccine (rBet v 1)
Number of subjects: 134
Study 19000581 — intervention group
Group type: EXPERIMENTAL
Intervention: natural purified birch pollen allergen (nBet v 1)
Number of subjects: 134
Study 19000581 — intervention group
Group type: EXPERIMENTAL
Intervention: licensed birch pollen extract
Number of subjects: 134
Study 17200587 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification surgery
Number of subjects: 0
Study 12875064 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney-tonifying prescription and routine western drugs
Number of subjects: 45
Study 12875064 — intervention group
Group type: COMPARATOR
Intervention: Routine western drugs
Number of subjects: 45
Study 11794070 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO formula vaccines
Number of subjects: 3
Study 11794070 — intervention group
Group type: COMPARATOR
Intervention: FDA formula vaccines
Number of subjects: 3
Study 9124058 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral challenge test with boiled egg and freeze-dried egg white
Number of subjects: 1
Study 9124058 — intervention group
Group type: COMPARATOR
Intervention: Double-blind, placebo-controlled food challenge using freeze-dried egg white
Number of subjects: 1
Study 9124058 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 min patch test with raw egg white
Number of subjects: 1
Study 9124058 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 min patch test with freeze-dried egg white
Number of subjects: 1
Study 9124058 — intervention group
Group type: EXPERIMENTAL
Intervention: RAST inhibition assays
Number of subjects: 1
Study 9124058 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE antibody titers to egg white components
Number of subjects: 1
Study 9124058 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE antibody titers for ovomucoid fragments digested by pepsin, chymotrypsin, and trypsin
Number of subjects: 1
Study 8238680 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visitation with husband participation
Number of subjects: 527
Study 8238680 — intervention group
Group type: COMPARATOR
Intervention: Home visitation without husband participation (control)
Number of subjects: 527
Study 3484552 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity TENS to appropriate acupuncture points
Number of subjects: 45
Study 3484552 — intervention group
Group type: COMPARATOR
Intervention: High intensity TENS to inappropriate (placebo) acupuncture points
Number of subjects: 45
Study 3484552 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 30504728 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral custom-made AFO plus walking shoes
Number of subjects: 44
Study 30504728 — intervention group
Group type: COMPARATOR
Intervention: Walking shoes alone (Control Group)
Number of subjects: 44
Study 27873388 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 60 mg three times a day
Number of subjects: 52
Study 27873388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 25421976 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nitrate (250 mL daily, as beetroot juice)
Number of subjects: 68
Study 25421976 — intervention group
Group type: COMPARATOR
Intervention: Placebo (250 mL daily, as nitrate-free beetroot juice)
Number of subjects: 68
Study 24350416 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine hydrochloride (3 ml, 4.5 mg) dripped on ETT cuff
Number of subjects: 86
Study 24350416 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 86